Nektar Therapeutics (NKTR) is back in focus after positive mid stage data in alopecia areata and plans to start late stage trials in atopic dermatitis, raising questions about what the pipeline could mean for the stock.

Nektar Therapeutics’ recent 10.3% 1 day share price return to US$71.04 and 23.9% 1 month share price return suggest momentum has picked up again, alongside index inclusions and fresh enthusiasm around its autoimmune pipeline, despite a 3 month share price decline of 4.9% and a very large 3 year total shareholder return of more than 7x.

If the recent move in Nektar Therapeutics has you looking beyond a single stock, this is a good moment to see what else is moving across 40 healthcare AI stocks.

With Nektar Therapeutics now in multiple Russell indices, a recent share price around US$71, a very large multi year return and a sizeable discount to analyst targets, investors have to ask: is there still an opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 53.6% Undervalued

Compared with Nektar Therapeutics' last close at $71.04, the most widely followed narrative applies a fair value of $153.25, creating a wide valuation gap that hinges largely on expectations for rezpegaldesleukin and the broader autoimmune pipeline.

Strong initial Phase IIb and ongoing data for REZPEG in atopic dermatitis, combined with a large and growing addressable market (expected to reach nearly $30B by 2033), position Nektar to access significant new revenue streams and improve long-term earnings as the population ages and chronic inflammatory diseases rise globally.

Curious what kind of revenue path, margin shift and future earnings multiple are being used to support that valuation gap? The narrative leans on aggressive revenue expansion, a sharp turn in profitability and a premium future earnings multiple that is far above typical sector benchmarks.

Result: Fair Value of $153.25 (UNDERVALUED)

However, this undervalued case for Nektar Therapeutics still leans heavily on REZPEG clearing late stage hurdles, as well as on the company managing ongoing losses and funding needs.

Another View on Nektar Therapeutics: What P/S Says

While the fair value narrative for Nektar Therapeutics points to a large upside gap, the current P/S ratio of 43.1x tells a very different story. It is well above the US Pharmaceuticals industry average of 6.7x, above the peer average of 12x, and above the fair ratio of 17.7x that our model suggests the market could move toward over time.

In practice, that means a lot of future success already appears built into the price on this metric. Any shortfall in execution or timelines could matter more than usual, while outperformance could keep the premium intact longer than skeptics expect.

Next Steps

With sentiment around Nektar Therapeutics clearly split between concern and optimism, take a moment to review the data for yourself and move quickly to shape your own view by weighing its 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond Nektar Therapeutics?

If Nektar Therapeutics has caught your attention, do not stop at a single stock. Use the tools available, compare ideas and keep your watchlist working for you.

• Target potential mispricings across the market by reviewing companies flagged in the 44 high quality undervalued stocks.
• Strengthen your downside protection by focusing on companies highlighted in the 74 resilient stocks with low risk scores.
• Spot earlier stage opportunities with strong financial quality by scanning the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.